Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ...
Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 Background: Preclinical evidence has shown that in xenograft mode...
In all clinical trials of patients with metastatic breast cancer, weekly intravenous infusions of trastuzumab produced a volume of distribution which approximated that of serum volume (2.95L). As only minimal amounts of trastuzumab penetrate into the cerebrospinal fluid, a response to trastuzumab would...
Used in combination to treat Metastatic breast cancer Regimen in combination with: Pertuzumab (DB06366), Hyaluronidase (human recombinant) (DB06205), Docetaxel (DB01248) •••••••••••• ••••• •• ••••• ••••••••...
Trastuzumab (Herceptin®) is a humanized IgG1 κ monoclonal antibody, specifically targeted against the extracellular domain of the human epidermal
It can be used alone or with other cancer medicines (eg, carboplatin, cyclophosphamide, docetaxel, doxorubicin, paclitaxel). Trastuzumab injection is also used in combination with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic (cancer that has spread) stomach and ...
In HER2-neoadjuvant setting (KRISTINE trial), “chemotherapy-free” regimen with T-DM1 plus pertuzumab combination compared to dual anti-HER2 blockade plus chemotherapy (docetaxel, carboplatin, trastuzumab, pertuzumab) resulted in a significantly lower rate of pCR (4...
Prior to institution of chemotherapy, breast MRI,18F-FDG- and64Cu-DT-PET were performed. Patients received intravenous trastuzumab, pertuzumab, docetaxel and carboplatin every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Response status was determined by surgical...
Jagiello-Gruszfeld AI, Rosinska M, Meluch M, Pogoda K, Niwinska A, Sienkiewicz R, Grous A, Winter P, Nowecki ZI: Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of...
Docetaxel Anthracyclines Everolimus Bisphosphonates Denosumab Trastuzumab Pertuzumab TDM1 SYD985Hyperaemia, ocular pain (severe in scleritis), photophobia, tearing, decrease in visual acuity (posterior scleritis)Topical lubricants Topical antibiotics ⁄ steroids ...